WHO Issues Concern Over Acute Scarcity of Weight-Loss Medications
Less than 10% of individuals that would benefit from weight-loss injections including Wegovy are able to get them, caution the WHO as it releases its first advice on the drugs.
With over a billion individuals worldwide currently living with obesity, it is advocating for increased and just access to GLP-1 medication.
According to estimates, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"The new guidance affirms that excess weight is a long-term condition that can be addressed with thorough and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major barriers to widespread access to the jabs that can assist patients in reducing significant weight, explains the body.
Skinny Jab Scarcity
Even under the present most favorable outlook, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – less than 10% of those who need them, as stated by the health organization.
The recommendation encourages governments and firms to widen access, by measures including patent sharing.
Exclusive production rights on a key compound – the core component of a leading brand – is scheduled to end in several countries in 2026.
How Obesity Injections Operate
GLP-1 drugs mimick a natural hormone to delay gastric emptying, curb appetite and boost the sense of being full so individuals reduce food intake.
People typically begin shedding pounds after several weeks of commencing the weekly injections.
Studies points to patients may see weight return after a year of discontinuing the drug, when their usual food cravings resume.
Being above a healthy weight increases your chance for contracting medical conditions, like diabetes, heart disease, stroke, and some malignancies.
Excess weight affects individuals in every country and was responsible for millions of fatalities worldwide in 2024, per the WHO.
